Intshayelelo
I-Tirzepatide, ephuhliswe ngu-Eli Lilly, lichiza le-peptide yenoveli emele isiganeko esibalulekileyo kunyango lwe-2 yeswekile kunye nokutyeba. Ngokungafaniyo neGLP-1 yemveli (iglucagon-like peptide-1) agonists, iTirzepatide isebenzazombini i-GIP (i-insulinotropic polypeptide exhomekeke kwiglucose)kwayeIi-receptors ze-GLP-1, ukuzuza igama elithi aI-agonist ye-receptor ezimbini. Le ndlela imbini inika amandla amandla aphezulu ekulawuleni i-glucose yegazi kunye nokunciphisa ubunzima bomzimba, ngakumbi kwizigulane ezinesifo sikashukela sohlobo lwe-2 kunye nokukhuluphala.
Indlela yokwenza
-
GIP receptor kusebenze: Ukuphucula ukukhutshwa kwe-insulin kunye nokuphucula ukunyamezela kwe-glucose.
-
GLP-1 receptor kusebenze: Ikhuthaza ukukhutshwa kwe-insulin, icinezela ukukhutshwa kweglucagon, kwaye icothise ukuphuma kwesisu.
-
Intsebenziswano kabini: Ukubonelela ngolawulo olusebenzayo lwe-glycemic kunye nokunciphisa ubunzima obunzima.
Uhlalutyo lweenkcukacha zeklinikhi
1. Uvavanyo lwe-SURPASS (uHlobo lwesi-2 seswekile)
Ngaphakathi kwezininziSURPASS izilingo zeklinikhi, I-Tirzepatide iphumelele i-insulin kunye ne-Semaglutide kwi-glycemic kunye neziphumo zokunciphisa ubunzima.
| Iqela lezigulane | Ithamo | Avg. Ukunciphisa i-HbA1c | Avg. Ukuhla ukusinda |
|---|---|---|---|
| Uhlobo lwesi-2 seswekile | 5 mg | -2.0% | -7.0 kg |
| Uhlobo lwesi-2 seswekile | 10 mg | -2.2% | -9.5 kg |
| Uhlobo lwesi-2 seswekile | 15 mg | -2.4% | -11.0 kg |
➡ Xa kuthelekiswa ne-Semaglutide (1 mg: HbA1c -1.9%, Ubunzima -6.0 kg), i-Tirzepatide ibonise iziphumo eziphakamileyo kulawulo lwe-glycemic kunye nokulahlekelwa kwesisindo.
2. SURMOUNT Izilingo (Ukutyeba)
Kwizigulana ezityebe ngokugqithiseleyo ezingenaso isifo seswekile, iTirzepatide ibonise ukusebenza kakuhle kokwehla kobunzima.
| Ithamo | Avg. Ukunciphisa Ubunzima (iiveki ezingama-72) |
|---|---|
| 5 mg | -15% |
| 10 mg | -20% |
| 15 mg | -22.5% |
➡ Kwisigulana esinobunzima obuyi-100 kg, idosi ephezulu ye-Tirzepatide inokunciphisa ubunzima obujikelezayo.22.5 kg.
Izinto Eziluncedo Ezingundoqo
-
Indlela ezimbini: Ngaphaya kwe-agonists eyodwa ye-GLP-1.
-
Ukusebenza okuphezulu: Isebenza kakuhle kulawulo lwe-glycemic kunye nolawulo lobunzima.
-
Ukusetyenziswa okubanzi: Ilungele zombini isifo seswekile kunye nokutyeba.
-
Amandla emarike aphezulu: Ukunyuka kwemfuno yezikhundla zonyango lokutyeba iTirzepatide njengeyeza le-blockbuster elizayo.
Imbonakalo yeMarike
-
Uqikelelo lobungakanani bemarike: Ngo-2030, imakethi yehlabathi ye-GLP-1 kuqikelelwa ukuba iya kudlulaI-USD 150 yezigidigidi, kunye neTirzepatide ekunokwenzeka ukuba ibambe isabelo esikhulu.
-
Imeko yokhuphiswano: Imbangi ephambili yiSemaglutide kaNovo Nordisk (Ozempic, Wegovy).
-
Inzuzo: Idatha yeklinikhi ibonisa i-Tirzepatide inikezela ukulahlekelwa kwesisindo esiphezulu xa kuthelekiswa ne-Semaglutide, ukuqinisa ukukhuphisana kwayo kweemarike kunyango lokukhuluphala.
Ixesha lokuposa: Sep-12-2025